Melanoma Management最新文献

Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients. 辅助全身治疗在不符合条件的III期和IV期黑色素瘤切除患者中的疗效和安全性。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-02-17 DOI: 10.1080/20450885.2025.2461963

Sarah Alsadiq, Adi Kartolo, Elaine McWhirter, Wilma Hopman, Tara Baetz

{"title":"Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients.","authors":"Sarah Alsadiq, Adi Kartolo, Elaine McWhirter, Wilma Hopman, Tara Baetz","doi":"10.1080/20450885.2025.2461963","DOIUrl":"10.1080/20450885.2025.2461963","url":null,"abstract":"Background: Adjuvant immunotherapy and targeted therapy are now the standard of care for patients with resected stage IIIA-IV melanoma. However, little is known regarding its efficacy in real-world patients who were not represented in these landmark trials.Methods: This retrospective study included all patients with resected stage IIIA-IV melanoma who received adjuvant systemic therapy between January 1 2018 and December 31 2020, in two Canadian academic cancer. Primary outcome was the proportion of trial non-eligible patients in the real-world setting. Survival and safety analyses were also conducted.Results: Of the total 113 patient, 99 (88%) were trial non-eligible patients. Most common reasons for trial non-eligible criteria was having no baseline CLND (72%), followed by outside of treatment window >12 weeks (30%), stage IIIA (14%), unknown primary (9%), stage IV (14%), and baseline AD on immunosuppressants (3%). There were no significant RFS (P = 0.731) or OS (P = 0.110) differences in the overall population of trial eligible vs. non-eligible. Safety profiles were similar between the trial eligible vs. non-eligible groups.Conclusion: Our study suggested a high proportion of real-world patients would have been deemed non-eligible for clinical trials. Regardless, adjuvant systemic therapy delivered similar survival and toxicity outcomes in both groups.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2461963"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beliefs and attitudes toward skin biopsy as a diagnostic tool: a cross-sectional survey among US patients. 对皮肤活检作为诊断工具的信念和态度：美国患者的横断面调查。

IF 0.7

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-09-29 DOI: 10.1080/20450885.2025.2564060

Chaitra Subramanyam, Nimrit Gahoonia, Catherine Shachaf, Raja Sivamani

{"title":"Beliefs and attitudes toward skin biopsy as a diagnostic tool: a cross-sectional survey among US patients.","authors":"Chaitra Subramanyam, Nimrit Gahoonia, Catherine Shachaf, Raja Sivamani","doi":"10.1080/20450885.2025.2564060","DOIUrl":"10.1080/20450885.2025.2564060","url":null,"abstract":"Aims: Skin biopsy remains the diagnostic gold standard for assessing melanocytic lesions, yet its use is influenced by provider experience and scope of practice. This study evaluated patient attitudes toward biopsy, barriers such as discomfort and needle phobia, and interest in noninvasive alternatives.Patients and methods: A cross-sectional survey of 506 adults assessed prior biopsy experience, biopsy-related discomfort, recovery time, anesthesia pain, needle fear and willingness to pay for noninvasive tools.Results: Twenty-eight percent of respondents had undergone biopsy. Of these, two-thirds reported discomfort and 28% rated it moderate to high. Recovery lasted ≥1 week for 59%, ≥2 weeks for 18%, and ≥1 month for 7%. Anesthesia was moderately to very painful for 33%. Common concerns included pain, scarring, infection risk and prolonged healing. Among those with biopsy experience, 53% expressed strong interest in noninvasive diagnostics, and 82% were willing to pay out-of-pocket.Conclusions: Patient-reported pain, needle fear and prolonged recovery contribute to hesitancy toward biopsy. Strong interest in noninvasive methods underscores the need to advance alternatives such as reflective confocal microscopy, tape stripping and electrical impedance spectroscopy, while future studies should examine socioeconomic and access-related influences.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2564060"},"PeriodicalIF":0.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary dermal melanoma: a rare subtype of cutaneous melanoma. 原发性皮肤黑色素瘤：一种罕见的皮肤黑色素瘤亚型。

IF 0.7

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-08-29 DOI: 10.1080/20450885.2025.2550234

Erol Benlier, Fatih Akyar, Kübra Afşaroğlu Zöhra

引用次数: 0

Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project. 晚期brafv600突变黑色素瘤的个性化治疗：基于REMINISCENCE项目3例报告的综述

IF 0.7

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-08-28 DOI: 10.1080/20450885.2025.2545167

Christoffer Gebhardt, Dirk Debus, Peter Rohrer, Katharina C Kähler, Lukas Koch, Patrick Terheyden, Van Anh Nguyen

{"title":"Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project.","authors":"Christoffer Gebhardt, Dirk Debus, Peter Rohrer, Katharina C Kähler, Lukas Koch, Patrick Terheyden, Van Anh Nguyen","doi":"10.1080/20450885.2025.2545167","DOIUrl":"10.1080/20450885.2025.2545167","url":null,"abstract":"The management of advanced, unresectable, or metastatic BRAFV600-mutated melanoma is complex, particularly regarding therapy sequencing with targeted therapies (TT) and immune checkpoint inhibitors (ICI). The REMINISCENCE project aimed to enhance individualized therapy approaches by analyzing case reports of patients undergoing encorafenib and binimetinib (EB) therapy. This report discusses three melanoma patients with brain metastases treated in Germany and Austria, emphasizing personalized treatment strategies in BRAFV600-mutated melanoma, particularly when both ICI and TT are available. The timing for transitioning between therapies remains contentious, with many patients experiencing disease progression during or after adjuvant therapy. Findings from clinical trials like DREAMseq, SECOMBIT, EBIN, and ImmunoCobiVem may not directly apply to this evolving clinical landscape due to the impact of prior therapies on the tumor microenvironment. The variations in trial designs further complicate sequencing strategies. Emerging methods, such as early circulating tumor DNA (ctDNA)-guided approaches, present potential pathways for personalized treatment. Ongoing research into sequencing therapy is crucial for improving clinical outcomes. To determine the most effective treatment sequences based on individual medical histories, genetic profiles, and treatment goals, there is an urgent need for prospective biomarker-driven clinical trials.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2545167"},"PeriodicalIF":0.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Threshold analysis of mortality outcomes in the collaborative ocular melanoma study (COMS). 协同眼黑色素瘤研究（COMS）死亡率结果的阈值分析。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-05-05 DOI: 10.1080/20450885.2025.2494977

Viktor T Gill, Shiva Sabazade, Gustav Stålhammar

{"title":"Threshold analysis of mortality outcomes in the collaborative ocular melanoma study (COMS).","authors":"Viktor T Gill, Shiva Sabazade, Gustav Stålhammar","doi":"10.1080/20450885.2025.2494977","DOIUrl":"https://doi.org/10.1080/20450885.2025.2494977","url":null,"abstract":"Aim: The collaborative ocular melanoma study (COMS) reported similar survival between plaque brachytherapy (a type of interventional radiotherapy) and enucleation for medium-sized choroidal melanomas. We aimed to quantify the mortality differences required to achieve statistical significance and assess the robustness of these thresholds.Methods: We reanalyzed 12-year mortality data from COMS using threshold analysis to determine how many additional or fewer deaths in either treatment arm would shift the lower bound of the 95% confidence interval (CI) for the risk ratio above 1.Results: At 12 years, there were 105 melanoma-related deaths in the brachytherapy arm and 98 in the enucleation arm (risk ratio 1.08, 95% CI 0.82-1.42). Achieving statistical significance would have required 31 additional deaths in the brachytherapy arm or 23 fewer in the enucleation arm; conversely, favoring brachytherapy would have necessitated 34 additional deaths in the enucleation arm or 27 fewer in the brachytherapy arm. These thresholds remained consistent across power levels and sensitivity scenarios.Conclusions: The COMS trial did not reveal a clinically meaningful survival difference. Our findings underscore the substantial mortality shifts required for statistical significance and highlight the challenges in detecting modest treatment effects in uveal melanoma trials.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2494977"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A bibliometric analysis of sentinel lymph node biopsy in melanoma of the top 90 cited publications. 前90位被引出版物中黑色素瘤前哨淋巴结活检的文献计量学分析。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-04-28 DOI: 10.1080/20450885.2025.2494979

Zhen Yu Wong, Aisha Chaudry, Samuel Teklay, Zhen Ning Wong, Oluwatobi Adegboye, Pojsakorn Danpanichkul, Ryan Faderani, Muholan Kanapathy, Afshin Mosahebi

{"title":"A bibliometric analysis of sentinel lymph node biopsy in melanoma of the top 90 cited publications.","authors":"Zhen Yu Wong, Aisha Chaudry, Samuel Teklay, Zhen Ning Wong, Oluwatobi Adegboye, Pojsakorn Danpanichkul, Ryan Faderani, Muholan Kanapathy, Afshin Mosahebi","doi":"10.1080/20450885.2025.2494979","DOIUrl":"https://doi.org/10.1080/20450885.2025.2494979","url":null,"abstract":"Background: This bibliometric analysis aims to describe research trends and assess the methodological quality of the highest-impact SLNB research in melanoma.Methods: We identified the 90 most cited publications on SLNB in melanoma using Web of Science, covering all available journal years (from 2005 to date). The Oxford Center for Evidence-Based Medicine (OCEBM) Levels of Evidence (LOE) were used to assess the methodological quality of each study.Results: The 90 most cited publications on SLNB in melanoma collectively garnered 10,314 citations. Citation counts per publication ranged from 44 to 1,405 (mean 114.6 ± 185.2), with the highest-cited study authored by Professor Donald Morton et al. The majority of publications was classified as LOE 3 (n = 36). The United States of America (USA) led in publication output with 43 articles. Professors Merrick Ross (USA) and John Thompson (Australia) were the leading authors by publication count. The University of Sydney (Australia), University of Texas System, and Anderson Cancer Center (USA) were the top contributing institutions. Annals of Surgical Oncology published most articles.Conclusions: This bibliometric analysis provides a comprehensive overview and valuable reference for future researchers in the field of SLNB in melanoma.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2494979"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case report of LVEF derived from gated FDG-PET: potential to streamline cardiotoxic surveillance in melanoma patients. 门控FDG-PET衍生的LVEF病例报告：简化黑色素瘤患者心脏毒性监测的潜力。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-05-28 DOI: 10.1080/20450885.2025.2510194

Marc Østergaard Nielsen, Johan Erik Larsson, Linus Daniel Leonhard Duchstein, Lars Thorbjørn Jensen

{"title":"Case report of LVEF derived from gated FDG-PET: potential to streamline cardiotoxic surveillance in melanoma patients.","authors":"Marc Østergaard Nielsen, Johan Erik Larsson, Linus Daniel Leonhard Duchstein, Lars Thorbjørn Jensen","doi":"10.1080/20450885.2025.2510194","DOIUrl":"10.1080/20450885.2025.2510194","url":null,"abstract":"Background: Advances in cancer therapy have improved patient outcomes, but cardiotoxicity remains a significant risk. In melanoma patients treated with BRAF and MEK inhibitors, monitoring left ventricular ejection fraction (LVEF) during treatment is recommended to detect cardiac dysfunction. Despite the widespread use of FDG-PET in oncology, its potential for concurrent cardiac assessment remains underexplored.Methods: A 42-year-old male undergoing treatment for disseminated melanoma underwent measurements of LVEF using four modalities: 3D-MUGA, 3D echocardiography, Rb-PET, and gated FDG-PET.Results: LVEF was within the normal range across all modalities: 60% (3D-MUGA), 61% (3D echocardiography), 63% (Rb-PET), and 65% (FDG-PET).Conclusion: This case presents an estimation of LVEF derived from a clinically indicated, FDG-PET scan, performed alongside three conventional modalities on the same day. This approach may be particularly useful in melanoma patients who undergo frequent FDG-PET scans. While the findings are promising, broader validation is needed.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2510194"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging gaps throughout a patient's journey with melanoma: a systematic review. 弥合患者与黑色素瘤之旅的差距：一项系统回顾。

IF 0.7

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-10-07 DOI: 10.1080/20450885.2025.2545169

Adil Amarsi, Joy Xu, Josh Chan, Yuan Chun Jiang, Ahmad Zobair Omar, Yasmin Meghdadi, Aashita Doshi, Alison Xie, Alyssa Wu

{"title":"Bridging gaps throughout a patient's journey with melanoma: a systematic review.","authors":"Adil Amarsi, Joy Xu, Josh Chan, Yuan Chun Jiang, Ahmad Zobair Omar, Yasmin Meghdadi, Aashita Doshi, Alison Xie, Alyssa Wu","doi":"10.1080/20450885.2025.2545169","DOIUrl":"https://doi.org/10.1080/20450885.2025.2545169","url":null,"abstract":"Background: Melanoma is one of the most fatal skin cancers, with rising incidence and mortality worldwide. From diagnosis to treatment, patient experiences often involve anxiety, symptom burden, and limited access to information which profoundly impacts health outcomes.Objective: This systematic review aims to identify and analyze major barriers melanoma patients face throughout their healthcare journey.Methods: Studies were identified from PubMed, Scopus, Web of Science, Embase, and Cochrane Library, supplemented by manual hand-searching. Eligible studies focused on the experiences of melanoma patients, addressed knowledge gaps and barriers to care throughout the patient journey, and were published in English between 2013 and 2023. Screening and extraction were conducted independently and in duplicate. The methodological quality of the included studies was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria.Results: Out of 2,257 screened articles, 183 met the inclusion criteria. Studies were categorized into four major themes: intersectionality, treatment, diagnosis/prognosis, and patient/societal burden. Commonly explored subcategories included self-examination, risk factors, and drug efficacy.Conclusions: Melanoma patients experience significant gaps throughout their healthcare journey. Identifying areas of improvement in current practices is the first step toward developing targeted solutions that improve the patient experience and quality of life.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2545169"},"PeriodicalIF":0.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening and novel diagnostic technologies for melanoma: an update. 黑色素瘤的筛查和新诊断技术：最新进展。

IF 0.7

Melanoma Management Pub Date : 2025-07-20 Epub Date: 2025-07-23 DOI: 10.1080/20450885.2025.2536999

Jonathan C Hwang, Bryan L Peacker, Rebecca I Hartman

引用次数: 0

Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes. 皮肤黑色素瘤的临床试验探索化学预防药物的最新进展：影响黑色素细胞的机制。

IF 1

Melanoma Management Pub Date : 2025-05-13 Epub Date: 2025-05-16 DOI: 10.1080/20450885.2025.2505400

Gelare Ghajar-Rahimi, Nabiha Yusuf

{"title":"Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes.","authors":"Gelare Ghajar-Rahimi, Nabiha Yusuf","doi":"10.1080/20450885.2025.2505400","DOIUrl":"10.1080/20450885.2025.2505400","url":null,"abstract":"Cutaneous melanoma is a highly aggressive skin cancer with rising incidence, driven by risk factors such as ultraviolet exposure, genetic predisposition, and immunosuppression. While surgical excision remains the primary treatment, interest in chemoprevention strategies is growing. Numerous natural and synthetic agents have shown preclinical promise, but evaluating their effectiveness is challenging due to their systemic effects on multiple cell types. This review provides a focused examination of the melanocyte-specific mechanisms of select agents that have been tested in clinical trials for melanoma chemoprevention. We discuss various molecular and cellular mechanisms driving the anti-melanoma properties of nonsteroidal anti-inflammatory drugs, statins, sulforaphane, vitamin D, and N-acetylcysteine. Despite promising preclinical and early clinical data, challenges remain regarding precise mechanisms, optimal dosing, long-term safety, and patient selection. Future research should focus on refining melanoma prevention strategies through well-designed clinical trials and personalized approaches integrating genetic and molecular risk factors.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2505400"},"PeriodicalIF":1.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0